Videos

A new study seeks to compare the outcomes of biopsies among American children at risk of celiac disease, with European thresholds that would deem such biopsies unnecessary.

The author of the largest clinical trial for pediatric PFIC to date discusses the various benefit maralixibat provides to disease managementr.

This interview segment with Dr. Harris-Tryon further explored some of the key points made in her upcoming talk regarding the microbiology of hidradenitis suppurativa.

During this interview, Dr. Harris-Tryon spoke about the most important points covered in her upcoming talk at the 8th Annual Symposium on Hidradenitis Suppurativa Advances.

This segment of Lungcast guest Dr. Barbara Taylor’s discussion covered the topic of new RSV vaccines as well as the spacing of others such as those of COVID-19 and influenza.

In this segment of Lungcast’s September episode, guest Dr. Barbara Taylor talked about the potential for a future universal flu vaccine as well as other potential advancements in the field.

In Lungcast’s September episode, guest Dr. Barbara Taylor discusses transmission and diagnosis of RSV as well as the possibility of a so-called ‘triple-demic.’

Sarah Wheeler, PharmD, and John Bucheit, PharmD, provide perspective on contemporary trends in screening and management of nonalcoholic fatty liver disease in people with type 2 diabetes.

The potassium-competitive acid blocker drug class is coming to US digestive disease management. How does it fare to standard antacids and PPIs for GERD?

This interview with Jayme Heim featured a discussion about some of the latest treatment-related news for atopic dermatitis and psoriasis.

New 3-year analysis shows a significant rate of patients were able to avoid relapse or hospitalization while receiving the long-acting injectable.

A trio of studies and new guidelines presented at the ESC Congress 2023 highlight advancement in the management of hypertrophic cardiomyopathy, particularly with use of mavacamten.

ORION-8 results showed the change in LDL-C from baseline in the 3-year open-label extension was similar to the change observed during 18 months of placebo-controlled comparison.

Javed Butler, MD, discusses the overall results of the STEP-HFpEF trial, how he interprets the reduction in adjudicated heart failure events, and how the community's recent experience with SGLT2 inhibitors might inform uptake strategies for semaglutide 2.4 mg.

A secondary analysis of the DELIVER trial found dapagliflozin significantly reduced the full spectrum of worsening heart failure events, including outpatient oral diuretic intensification.

Data support the benefit of bariatric surgery in patients at high risk of pancreatic ductal adenocarcinoma due to BMI and metabolic comorbidities.

While discussing a review of noninvasive options, the gastroenterologist addresses the growing interest in non-colonoscopy screening and surveillance methods.

Clayton, a primary investigator in the drug's pivotal trials, discusses what the historic FDA approval means for managing PPD in women.

Qazi reviews the selective JAK1 inhibitor's benefit for patients who previously failed TNF inhibitor regimen.

In this interview with Dr. Gold, she describes her team’s recent findings from a phase 4 head-to-head study on risankizumab for psoriasis patients.

Presented at ASRS 2023, pegcetacoplan injection showed increasing treatment effects over 30 months for patients with geographic atrophy, with a consistent safety profile to previous phase 3 data.

Late-breaking findings at ASRS 2023 suggest daily home OCT imaging is sufficient for remotely monitoring fluid among patients with treatment-naïve nAMD.

At ASRS 2023, results from the MOSAIC study indicate the substantial burden of geographic atrophy on patients and their caregivers across the United States and Canada.

Vogel reviews the struggles behind adequately diagnosing long Covid and quantifying its impact of disease at this time of clinical research.

Lungcast's July episode guest discusses how long Covid therapy development is still about 5 years away from the market.

Crisis Point returns with an episode on cardiometabolic health disparities, as 3 experts unravel the scope of the crisis, from its historical basis to ongoing social determinants of health in the modern age.

Juan Frias, MD, discusses the potential impact of an FDA approval for once-weekly insulin icodec based on data observed within the ONWARDS program.

A 7-year longitudinal analysis presented at ADA 2023 suggests time in range was associated with an increased risk of diabetic retinopathy in people with type 1 diabetes.